Difficulty: Medium
Average Score: 77%
Practice
Rheumatoid factor (RF)-positive polyarthritis usually accounts for
Correct answer
A
Rationale
In the case of RF-positive polyarthritis in juvenile idiopathic arthritis (JIA) with involvement of 25 joints in both upper and lower extremities, the least effective drug to induce remission is NSAIDs (Option A).
The rationale behind this is that NSAIDs primarily target symptoms like pain and inflammation, but they do not address the underlying autoimmune process causing JIA. In contrast, methotrexate (Option B), TNF-a antagonists (Option C), and IL-6 inhibitors (Option D) are disease-modifying anti-rheumatic drugs (DMARDs) that target the underlying autoimmune response in JIA, leading to remission and preventing joint damage.
Methotrexate is a first-line DMARD commonly used in JIA treatment. TNF-a antagonists and IL-6 inhibitors are biologic DMARDs that specifically target key inflammatory pathways involved in JIA pathogenesis.
Educationally, understanding the mechanisms of action of different drug classes in treating JIA is crucial for healthcare providers managing pediatric patients with arthritis. It is essential to differentiate between symptomatic relief (NSAIDs) and disease-modifying treatment (DMARDs) to provide optimal care and improve long-term outcomes for children with JIA.
The rationale behind this is that NSAIDs primarily target symptoms like pain and inflammation, but they do not address the underlying autoimmune process causing JIA. In contrast, methotrexate (Option B), TNF-a antagonists (Option C), and IL-6 inhibitors (Option D) are disease-modifying anti-rheumatic drugs (DMARDs) that target the underlying autoimmune response in JIA, leading to remission and preventing joint damage.
Methotrexate is a first-line DMARD commonly used in JIA treatment. TNF-a antagonists and IL-6 inhibitors are biologic DMARDs that specifically target key inflammatory pathways involved in JIA pathogenesis.
Educationally, understanding the mechanisms of action of different drug classes in treating JIA is crucial for healthcare providers managing pediatric patients with arthritis. It is essential to differentiate between symptomatic relief (NSAIDs) and disease-modifying treatment (DMARDs) to provide optimal care and improve long-term outcomes for children with JIA.